MedTrace Logo

Polyprenols (Ropren) in Acute Coronary Syndrome

NCT03122340 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2018-04-26

No results posted yet for this study

Summary

The aim of this study is to determine efficacy and safety of polyprenols (ROPREN) using in patients with acute coronary syndrome

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

Ropren

Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks

OTHER

Oil

Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks

Sponsors & Collaborators

  • Tomsk National Research Medical Center of the Russian Academy of Sciences

    lead OTHER

Principal Investigators

  • Sergey V Popov, MD, PhD · Tomsk NRMC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-01
Primary Completion
2017-12-31
Completion
2018-02-28

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03122340 on ClinicalTrials.gov